Synthetic peptides induce a cytotoxic response against human papillomavirus type-18

被引:10
作者
Castellanos, MR [1 ]
Hayes, RL
Maiman, MA
机构
[1] Staten Isl Univ Hosp, Dept Obstet & Gynecol, Staten Isl, NY 10305 USA
[2] Nalitt Inst Canc & Blood Related Dis, Dept Med, Staten Isl, NY USA
[3] Nalitt Inst Canc & Blood Related Dis, Canc Immunotherapy Program, Staten Isl, NY USA
关键词
papillomavirus; human; cervical cancer; immunotherapy; vaccine; HLA-A2; antigens; cytotoxic T-lymphocytes;
D O I
10.1006/gyno.2001.6205
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. Over 90% of cervical carcinomas express human papillomavirus (HPV) E6 and E7 proteins. These unique antigens are ideal targets for the development of cytotoxic T-lymphocytes (CTL) for antitumor immunotherapy. In this study we identify peptides from HPV-18 E6 and E7 proteins that bind to HLA class I molecules. We further show that these peptides are able to induce peptide-specific CTL from an HLA-A2-positive (+) peripheral blood donor in vitro, Methods. A computer-assisted algorithm was devised to identify peptides from HPV-18 E6 and E7 proteins that bind to HLA-A2 molecules. Peptides that were predicted to bind were synthesized and their binding activity was determined. HLA-A2(+) irradiated stimulator cells pulsed with HPV-18 peptides were incubated with HLA-A2(+) peripheral blood mononuclear cells. Cytotoxicity assays were performed to assess specific cell lysis, Results. Of 295 possible sequences, the computer-assisted algorithm predicted 10 peptides that would have a high probability of binding to HLA-A2. The 4 strongest binding peptides were analyzed for their ability to induce cytotoxic cells against HPV-18 peptide-pulsed targets. Two of the peptides induced significant lysis. Conclusions, There are limited data on peptide-based immunotherapy for HPV-18(+) tumors. The combination of our computer-assisted algorithm and binding assay permits rapid selection of potential CTL epitopes, We identified two peptides that were able to induce peptide-specific lysis. These two epitopes are candidates for a peptide-based vaccine against HPV-18(+) tumors. The model described has broad applications and can be used in the development of immunotherapy for other types of cancers. (C) 2001 Academic Press.
引用
收藏
页码:77 / 83
页数:7
相关论文
共 23 条
[1]   Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope [J].
Alexander, M ;
Salgaller, ML ;
Celis, E ;
Sette, A ;
Barnes, WA ;
Rosenberg, SA ;
Steller, MA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (06) :1586-1593
[2]  
[Anonymous], 1993, INT J CANCER, DOI DOI 10.1002/ijc.2910540413
[3]   HUMAN PAPILLOMAVIRUSES, CERVICAL-CANCER AND THE DEVELOPING-WORLD [J].
BIRLEY, HDL .
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1995, 89 (05) :453-463
[4]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[5]   Medical progress - Cancer of the uterine cervix [J].
Cannistra, SA ;
Niloff, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1030-1038
[6]  
CASTELLANOS MR, UNPUB SIMPLE ALGORIT
[7]  
FELTKAMP MC, 1994, EUR J IMMUNOL, V23, P2242
[8]   CYTOTOXIC T-LYMPHOCYTES RAISED AGAINST A SUBDOMINANT EPITOPE OFFERED AS A SYNTHETIC PEPTIDE ERADICATE HUMAN PAPILLOMAVIRUS TYPE 16-INDUCED TUMORS [J].
FELTKAMP, MCW ;
VREUGDENHIL, GR ;
VIERBOOM, RPM ;
RAS, E ;
VANDERBURG, SH ;
TERSCHEGGET, J ;
MELIEF, CJM ;
KAST, WM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2638-2642
[9]   Risk factors for rapid-onset cervical cancer [J].
Hildesheim, A ;
Hadjimichael, O ;
Schwartz, PE ;
Wheeler, CM ;
Barnes, W ;
Lowell, DM ;
Willett, J ;
Schiffman, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 180 (03) :571-577
[10]  
KAST WM, 1994, J IMMUNOL, V152, P3904